25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ADMA (ADMA Biologics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze ADMA Biologics Inc together

I guess you are interested in ADMA Biologics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – ADMA Biologics Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – ADMA Biologics Inc’s Price Targets

I'm going to help you getting a better view of ADMA Biologics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about ADMA Biologics Inc

I send you an email if I find something interesting about ADMA Biologics Inc.

1. Quick Overview

1.1. Quick analysis of ADMA Biologics Inc (30 sec.)










1.2. What can you expect buying and holding a share of ADMA Biologics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$1.60
Expected worth in 1 year
$2.43
How sure are you?
45.0%

+ What do you gain per year?

Total Gains per Share
$0.82
Return On Investment
5.4%

For what price can you sell your share?

Current Price per Share
$15.16
Expected price per share
$13.50 - $16.62
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of ADMA Biologics Inc (5 min.)




Live pricePrice per Share (EOD)
$15.16
Intrinsic Value Per Share
$-0.01 - $9.11
Total Value Per Share
$1.60 - $10.71

2.2. Growth of ADMA Biologics Inc (5 min.)




Is ADMA Biologics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$398.3m$157.1m$181m53.5%

How much money is ADMA Biologics Inc making?

Current yearPrevious yearGrowGrow %
Making money$52.2m$8.6m$43.5m83.3%
Net Profit Margin44.2%7.9%--

How much money comes from the company's main activities?

2.3. Financial Health of ADMA Biologics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#140 / 849

Most Revenue
#78 / 849

Most Profit
#39 / 849
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of ADMA Biologics Inc?

Welcome investor! ADMA Biologics Inc's management wants to use your money to grow the business. In return you get a share of ADMA Biologics Inc.

First you should know what it really means to hold a share of ADMA Biologics Inc. And how you can make/lose money.

Speculation

The Price per Share of ADMA Biologics Inc is $15.16. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of ADMA Biologics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in ADMA Biologics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.60. Based on the TTM, the Book Value Change Per Share is $0.21 per quarter. Based on the YOY, the Book Value Change Per Share is $0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of ADMA Biologics Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.140.9%0.211.4%0.040.2%0.070.5%0.010.1%-0.02-0.1%
Usd Book Value Change Per Share0.080.5%0.211.4%0.040.3%0.090.6%0.060.4%0.040.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.080.5%0.211.4%0.040.3%0.090.6%0.060.4%0.040.3%
Usd Price Per Share18.21-18.80-6.47-9.53-6.42-5.64-
Price to Earnings Ratio33.07-30.42-27.80-11.72-4.68--17.49-
Price-to-Total Gains Ratio239.48-144.81-71.32-113.80-39.87--42.84-
Price to Book Ratio11.37-14.39-9.56-9.92-7.60--215.21-
Price-to-Total Gains Ratio239.48-144.81-71.32-113.80-39.87--42.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share15.16
Number of shares65
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.210.06
Usd Total Gains Per Share0.210.06
Gains per Quarter (65 shares)13.404.19
Gains per Year (65 shares)53.6116.77
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1054440177
201079803324
3016115205041
4021420616758
5026826018375
60322314110092
703753681116109
804294221133126
904824761150143
1005365301166160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%7.05.00.058.3%7.013.00.035.0%7.033.00.017.5%7.068.00.09.3%
Book Value Change Per Share4.00.00.0100.0%9.03.00.075.0%12.08.00.060.0%18.022.00.045.0%24.037.014.032.0%
Dividend per Share0.00.04.00.0%2.00.010.016.7%2.00.018.010.0%2.00.038.05.0%2.00.073.02.7%
Total Gains per Share4.00.00.0100.0%9.03.00.075.0%12.08.00.060.0%18.022.00.045.0%24.037.014.032.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of ADMA Biologics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0760.206-63%0.041+87%0.094-19%0.064+19%0.039+95%
Book Value Per Share--1.6021.374+17%0.656+144%0.867+85%0.702+128%0.403+298%
Current Ratio--5.3326.241-15%5.946-10%6.184-14%6.799-22%6.286-15%
Debt To Asset Ratio--0.2870.312-8%0.554-48%0.487-41%0.517-45%0.676-58%
Debt To Equity Ratio--0.4020.463-13%1.255-68%1.070-62%1.167-66%2.477-84%
Dividend Per Share----0%-0%0.001-100%0.000-100%0.000-100%
Enterprise Value--4457390056.6004562134251.650-2%1424385745.065+213%2215611852.146+101%1462525774.685+205%1298244128.874+243%
Eps--0.1380.212-35%0.036+283%0.069+100%0.010+1215%-0.018+113%
Ev To Ebitda Ratio--25.33228.089-10%5.482+362%24.155+5%11.869+113%-17.043+167%
Ev To Sales Ratio--9.1359.628-5%4.077+124%5.621+63%5.333+71%45.882-80%
Free Cash Flow Per Share--0.0750.067+12%0.069+10%0.027+176%-0.033+143%-0.044+158%
Free Cash Flow To Equity Per Share--0.0750.002+3347%0.026+187%0.013+480%0.003+2487%0.006+1248%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--9.108----------
Intrinsic Value_10Y_min---0.005----------
Intrinsic Value_1Y_max--0.226----------
Intrinsic Value_1Y_min---0.146----------
Intrinsic Value_3Y_max--1.202----------
Intrinsic Value_3Y_min---0.316----------
Intrinsic Value_5Y_max--2.809----------
Intrinsic Value_5Y_min---0.349----------
Market Cap3617641700.040-25%4527160056.6004623091501.650-2%1553824858.565+191%2323653359.229+95%1561830095.635+190%1361563244.824+232%
Net Profit Margin--0.2810.442-36%0.079+255%0.084+234%-0.367+231%-1.432+610%
Operating Margin--0.3440.327+5%0.154+124%0.129+166%-0.250+173%-1.242+461%
Operating Ratio--0.6490.669-3%0.762-15%0.841-23%1.223-47%2.239-71%
Pb Ratio9.462-20%11.36514.388-21%9.562+19%9.924+15%7.604+49%-215.212+1994%
Pe Ratio27.535-20%33.07530.419+9%27.801+19%11.715+182%4.680+607%-17.490+153%
Price Per Share15.160-20%18.21018.798-3%6.470+181%9.532+91%6.422+184%5.644+223%
Price To Free Cash Flow Ratio50.341-20%60.46920.817+190%-8.663+114%-2.041+103%-2.793+105%-23.616+139%
Price To Total Gains Ratio199.367-20%239.477144.808+65%71.319+236%113.801+110%39.868+501%-42.840+118%
Quick Ratio--2.6692.918-9%2.143+25%2.422+10%2.684-1%3.525-24%
Return On Assets--0.0610.109-44%0.022+173%0.030+101%-0.014+122%-0.088+244%
Return On Equity--0.0860.158-46%0.043+99%0.033+164%-0.054+163%-0.405+572%
Total Gains Per Share--0.0760.206-63%0.041+87%0.094-19%0.064+18%0.039+93%
Usd Book Value--398325000.000338163000.000+18%157154586.500+153%210503816.417+89%169752756.000+135%97280223.900+309%
Usd Book Value Change Per Share--0.0760.206-63%0.041+87%0.094-19%0.064+19%0.039+95%
Usd Book Value Per Share--1.6021.374+17%0.656+144%0.867+85%0.702+128%0.403+298%
Usd Dividend Per Share----0%-0%0.001-100%0.000-100%0.000-100%
Usd Enterprise Value--4457390056.6004562134251.650-2%1424385745.065+213%2215611852.146+101%1462525774.685+205%1298244128.874+243%
Usd Eps--0.1380.212-35%0.036+283%0.069+100%0.010+1215%-0.018+113%
Usd Free Cash Flow--18717000.00016523250.000+13%16529564.750+13%6734993.500+178%-7662079.350+141%-10381051.400+155%
Usd Free Cash Flow Per Share--0.0750.067+12%0.069+10%0.027+176%-0.033+143%-0.044+158%
Usd Free Cash Flow To Equity Per Share--0.0750.002+3347%0.026+187%0.013+480%0.003+2487%0.006+1248%
Usd Market Cap3617641700.040-25%4527160056.6004623091501.650-2%1553824858.565+191%2323653359.229+95%1561830095.635+190%1361563244.824+232%
Usd Price Per Share15.160-20%18.21018.798-3%6.470+181%9.532+91%6.422+184%5.644+223%
Usd Profit--34219000.00052232000.000-34%8697130.500+293%15988962.083+114%1746457.300+1859%-4786903.500+114%
Usd Revenue--121984000.000118543500.000+3%82561068.750+48%84377216.000+45%59035488.100+107%32070441.600+280%
Usd Total Gains Per Share--0.0760.206-63%0.041+87%0.094-19%0.064+18%0.039+93%
 EOD+4 -4MRQTTM+16 -21YOY+32 -53Y+28 -115Y+31 -810Y+30 -9

3.3 Fundamental Score

Let's check the fundamental score of ADMA Biologics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1527.535
Price to Book Ratio (EOD)Between0-19.462
Net Profit Margin (MRQ)Greater than00.281
Operating Margin (MRQ)Greater than00.344
Quick Ratio (MRQ)Greater than12.669
Current Ratio (MRQ)Greater than15.332
Debt to Asset Ratio (MRQ)Less than10.287
Debt to Equity Ratio (MRQ)Less than10.402
Return on Equity (MRQ)Greater than0.150.086
Return on Assets (MRQ)Greater than0.050.061
Total7/10 (70.0%)

3.4 Technical Score

Let's check the technical score of ADMA Biologics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.596
Ma 20Greater thanMa 5014.728
Ma 50Greater thanMa 10015.879
Ma 100Greater thanMa 20017.224
OpenGreater thanClose14.710
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About ADMA Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Fundamental data was last updated by Penke on 2025-10-16 17:13:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit ADMA Biologics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 28.1% means that $0.28 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ADMA Biologics Inc:

  • The MRQ is 28.1%. The company is making a huge profit. +2
  • The TTM is 44.2%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ28.1%TTM44.2%-16.1%
TTM44.2%YOY7.9%+36.3%
TTM44.2%5Y-36.7%+80.8%
5Y-36.7%10Y-143.2%+106.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ28.1%-76.0%+104.1%
TTM44.2%-167.3%+211.5%
YOY7.9%-186.4%+194.3%
3Y8.4%-263.9%+272.3%
5Y-36.7%-345.5%+308.8%
10Y-143.2%-477.5%+334.3%
4.3.1.2. Return on Assets

Shows how efficient ADMA Biologics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • 6.1% Return on Assets means that ADMA Biologics Inc generated $0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ADMA Biologics Inc:

  • The MRQ is 6.1%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 10.9%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ6.1%TTM10.9%-4.7%
TTM10.9%YOY2.2%+8.6%
TTM10.9%5Y-1.4%+12.2%
5Y-1.4%10Y-8.8%+7.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1%-12.0%+18.1%
TTM10.9%-11.9%+22.8%
YOY2.2%-11.0%+13.2%
3Y3.0%-12.0%+15.0%
5Y-1.4%-11.7%+10.3%
10Y-8.8%-13.8%+5.0%
4.3.1.3. Return on Equity

Shows how efficient ADMA Biologics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • 8.6% Return on Equity means ADMA Biologics Inc generated $0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ADMA Biologics Inc:

  • The MRQ is 8.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 15.8%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ8.6%TTM15.8%-7.2%
TTM15.8%YOY4.3%+11.5%
TTM15.8%5Y-5.4%+21.3%
5Y-5.4%10Y-40.5%+35.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.6%-14.2%+22.8%
TTM15.8%-14.8%+30.6%
YOY4.3%-15.0%+19.3%
3Y3.3%-16.6%+19.9%
5Y-5.4%-16.9%+11.5%
10Y-40.5%-19.5%-21.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of ADMA Biologics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient ADMA Biologics Inc is operating .

  • Measures how much profit ADMA Biologics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • An Operating Margin of 34.4% means the company generated $0.34  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ADMA Biologics Inc:

  • The MRQ is 34.4%. The company is operating very efficient. +2
  • The TTM is 32.7%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ34.4%TTM32.7%+1.7%
TTM32.7%YOY15.4%+17.3%
TTM32.7%5Y-25.0%+57.7%
5Y-25.0%10Y-124.2%+99.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ34.4%-153.1%+187.5%
TTM32.7%-265.6%+298.3%
YOY15.4%-246.9%+262.3%
3Y12.9%-247.4%+260.3%
5Y-25.0%-338.0%+313.0%
10Y-124.2%-498.1%+373.9%
4.3.2.2. Operating Ratio

Measures how efficient ADMA Biologics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.65 means that the operating costs are $0.65 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ADMA Biologics Inc:

  • The MRQ is 0.649. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.669. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.649TTM0.669-0.020
TTM0.669YOY0.762-0.092
TTM0.6695Y1.223-0.554
5Y1.22310Y2.239-1.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6491.868-1.219
TTM0.6692.773-2.104
YOY0.7622.820-2.058
3Y0.8413.575-2.734
5Y1.2234.664-3.441
10Y2.2396.406-4.167
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of ADMA Biologics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if ADMA Biologics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.33 means the company has $5.33 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ADMA Biologics Inc:

  • The MRQ is 5.332. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.241. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.332TTM6.241-0.909
TTM6.241YOY5.946+0.295
TTM6.2415Y6.799-0.558
5Y6.79910Y6.286+0.513
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3323.414+1.918
TTM6.2413.605+2.636
YOY5.9464.036+1.910
3Y6.1844.431+1.753
5Y6.7995.716+1.083
10Y6.2866.128+0.158
4.4.3.2. Quick Ratio

Measures if ADMA Biologics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 2.67 means the company can pay off $2.67 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ADMA Biologics Inc:

  • The MRQ is 2.669. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.918. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.669TTM2.918-0.249
TTM2.918YOY2.143+0.775
TTM2.9185Y2.684+0.234
5Y2.68410Y3.525-0.841
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6692.911-0.242
TTM2.9183.135-0.217
YOY2.1433.825-1.682
3Y2.4224.359-1.937
5Y2.6845.692-3.008
10Y3.5256.524-2.999
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of ADMA Biologics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of ADMA Biologics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare ADMA Biologics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.29 means that ADMA Biologics Inc assets are financed with 28.7% credit (debt) and the remaining percentage (100% - 28.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ADMA Biologics Inc:

  • The MRQ is 0.287. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.312. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.287TTM0.312-0.025
TTM0.312YOY0.554-0.242
TTM0.3125Y0.517-0.205
5Y0.51710Y0.676-0.159
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2870.342-0.055
TTM0.3120.360-0.048
YOY0.5540.331+0.223
3Y0.4870.344+0.143
5Y0.5170.348+0.169
10Y0.6760.378+0.298
4.5.4.2. Debt to Equity Ratio

Measures if ADMA Biologics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 40.2% means that company has $0.40 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ADMA Biologics Inc:

  • The MRQ is 0.402. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.463. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.402TTM0.463-0.062
TTM0.463YOY1.255-0.792
TTM0.4635Y1.167-0.703
5Y1.16710Y2.477-1.311
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4020.399+0.003
TTM0.4630.439+0.024
YOY1.2550.429+0.826
3Y1.0700.471+0.599
5Y1.1670.471+0.696
10Y2.4770.518+1.959
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings ADMA Biologics Inc generates.

  • Above 15 is considered overpriced but always compare ADMA Biologics Inc to the Biotechnology industry mean.
  • A PE ratio of 33.07 means the investor is paying $33.07 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ADMA Biologics Inc:

  • The EOD is 27.535. Based on the earnings, the company is overpriced. -1
  • The MRQ is 33.075. Based on the earnings, the company is overpriced. -1
  • The TTM is 30.419. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD27.535MRQ33.075-5.540
MRQ33.075TTM30.419+2.656
TTM30.419YOY27.801+2.618
TTM30.4195Y4.680+25.739
5Y4.68010Y-17.490+22.170
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD27.535-2.877+30.412
MRQ33.075-2.296+35.371
TTM30.419-2.701+33.120
YOY27.801-3.622+31.423
3Y11.715-3.843+15.558
5Y4.680-6.007+10.687
10Y-17.490-6.984-10.506
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ADMA Biologics Inc:

  • The EOD is 50.341. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 60.469. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 20.817. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD50.341MRQ60.469-10.128
MRQ60.469TTM20.817+39.651
TTM20.817YOY-8.663+29.481
TTM20.8175Y-2.793+23.610
5Y-2.79310Y-23.616+20.823
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD50.341-3.674+54.015
MRQ60.469-2.920+63.389
TTM20.817-3.869+24.686
YOY-8.663-4.296-4.367
3Y-2.041-5.305+3.264
5Y-2.793-8.442+5.649
10Y-23.616-9.887-13.729
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of ADMA Biologics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 11.37 means the investor is paying $11.37 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ADMA Biologics Inc:

  • The EOD is 9.462. Based on the equity, the company is overpriced. -1
  • The MRQ is 11.365. Based on the equity, the company is expensive. -2
  • The TTM is 14.388. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD9.462MRQ11.365-1.904
MRQ11.365TTM14.388-3.022
TTM14.388YOY9.562+4.826
TTM14.3885Y7.604+6.784
5Y7.60410Y-215.212+222.816
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD9.4622.524+6.938
MRQ11.3652.062+9.303
TTM14.3882.248+12.140
YOY9.5622.465+7.097
3Y9.9242.704+7.220
5Y7.6043.834+3.770
10Y-215.2124.581-219.793
4.6.2. Total Gains per Share

2.4. Latest News of ADMA Biologics Inc

Does ADMA Biologics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from ADMA Biologics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-10-16
19:38
US High Growth Tech Stocks To Watch For Potential ExpansionRead
2025-10-10
23:50
Adma Biologics (ADMA) Stock Moves -1.36%: What You Should KnowRead
2025-10-09
21:26
Noteworthy Thursday Option Activity: GD, ADMA, ENPHRead
2025-09-30
13:38
Exploring 3 High Growth Tech Stocks In The US MarketRead
2025-09-29
13:38
High Growth Tech Stocks In The US Market With Promising PotentialRead
2025-09-25
19:38
Exploring High Growth Tech Stocks in the US MarketRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ADMA Biologics Inc.

4.8.1. Institutions holding ADMA Biologics Inc

Institutions are holding 90.324% of the shares of ADMA Biologics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30BlackRock Inc15.28440.012636473380-812928-2.1802
2025-06-30Vanguard Group Inc8.95260.006321363715452226626.852
2025-06-30Amvescap Plc.5.37150.039712818141-48763-0.379
2025-06-30State Street Corp5.06160.0082120785056377275.5742
2025-06-30Geode Capital Management, LLC2.47790.007659131212453094.3281
2025-06-30Nuveen, LLC2.33120.028556290484804317.9866
2025-06-30Dimensional Fund Advisors, Inc.1.9960.02014763075-97239-2.0007
2025-06-30American Century Companies Inc1.93230.045646109893586278.4336
2025-06-30Allspring Global Investments Holdings, LLC1.39140.099333202512713058.8983
2025-06-30Thrivent Financial For Lutherans1.38940.13213315425329634917280.0849
2025-06-30FMR Inc1.34630.00333212574-152421-4.5296
2025-06-30Renaissance Technologies Corp1.31840.07623146053-402935-11.3535
2025-06-30Oberweis Asset Management Inc1.31412.48443135890-290370-8.4748
2025-06-30Perpetual Ltd1.21290.61862894286-657527-18.5124
2025-06-30Franklin Resources Inc1.13940.01312719016108528666.4299
2025-06-30Charles Schwab Investment Management Inc1.04850.00792502026400211.6255
2025-06-30Driehaus Capital Management LLC1.0380.36092477013-469557-15.9357
2025-06-30Northern Trust Corp1.02390.00612443301-151455-5.837
2025-06-30UBS Group AG1.01480.00762421623-395191-14.0297
2025-06-30Ranger Investment Management LP1.00173.0398239037578686549.0714
Total 57.64637.0174137561663+8613412+6.3%

4.9.2. Funds holding ADMA Biologics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-08-31iShares Core S&P Small-Cap ETF5.94920.28721419655800
2025-07-31Vanguard Total Stock Mkt Idx Inv3.00490.0077170577-150886-2.0609
2025-08-31iShares Russell 2000 ETF2.33780.1451557865300
2025-08-31SPDR® S&P Biotech ETF1.36021.1109324592372350.2234
2025-07-31Vanguard Small Cap Index1.15250.0332750298-18300-0.661
2025-06-30American Century Small Cap Growth Inv1.0981.0323262011344791620.6204
2025-06-30American Century U.S. Small Cap Growth1.0981.0354262011344791620.6204
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr1.07530.05972566010-1115473-30.2996
2025-06-30Fidelity Small Cap Index0.97460.16552325812-2210-0.0949
2025-08-29SPDR® Portfolio S&P 600™ Sm Cap ETF0.88570.28742113462253441.2137
2025-07-31CREF Stock R30.86320.0296205977500
2025-08-31iShares S&P Small-Cap 600 Growth ETF0.86090.565205425500
2025-08-31iShares Russell 2000 Growth ETF0.85420.2841203829400
2025-07-31Invesco Main Street Small Cap R60.80641.7497192436725482315.263
2025-06-30Thrivent Small Cap Stock A0.7971.18231901835514802.7822
2025-06-30Ranger Small Cap0.79072.8852188688563006550.1317
2025-06-30Putnam US Small Cap Growth Managed Acct0.73131.1172174501047949237.889
2025-06-30Putnam US Small Cap Growth Equity0.73131.1172174501047949237.889
2025-07-31Putnam Small Cap Growth A0.73131.1199174501000
2025-06-30Invesco Small Cap Core0.69961.48751669544-326233-16.3462
Total 26.802115.701263957504+1210661+1.9%

5.3. Insider Transactions

Insiders are holding 2.568% of the shares of ADMA Biologics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-06-16Steve ElmsSELL19474920.24
2025-06-13Steve ElmsSELL13793120.82
2025-06-12Steve ElmsSELL9294121.69
2025-06-09Jerrold B GrossmanSELL1000021.31
2025-06-09Lawrence P GuiheenSELL2000020.96
2025-05-22Lawrence P GuiheenSELL122120.12
2025-05-21Lawrence P GuiheenSELL777920.32
2024-11-22Brad L TadeSELL1500021.15
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets558,380
Total Liabilities160,055
Total Stockholder Equity398,325
 As reported
Total Liabilities 160,055
Total Stockholder Equity+ 398,325
Total Assets = 558,380

Assets

Total Assets558,380
Total Current Assets399,563
Long-term Assets158,817
Total Current Assets
Cash And Cash Equivalents 90,285
Net Receivables 109,726
Inventory 191,464
Other Current Assets 8,088
Total Current Assets  (as reported)399,563
Total Current Assets  (calculated)399,563
+/-0
Long-term Assets
Property Plant Equipment 66,462
Goodwill 3,530
Intangible Assets 527
Long-term Assets Other 9,063
Long-term Assets  (as reported)158,817
Long-term Assets  (calculated)79,582
+/- 79,235

Liabilities & Shareholders' Equity

Total Current Liabilities74,941
Long-term Liabilities85,114
Total Stockholder Equity398,325
Total Current Liabilities
Short-term Debt 1,127
Accounts payable 29,769
Other Current Liabilities 41,202
Total Current Liabilities  (as reported)74,941
Total Current Liabilities  (calculated)72,098
+/- 2,843
Long-term Liabilities
Long term Debt 73,397
Capital Lease Obligations 10,428
Long-term Liabilities Other 940
Long-term Liabilities  (as reported)85,114
Long-term Liabilities  (calculated)84,765
+/- 349
Total Stockholder Equity
Common Stock24
Retained Earnings -247,460
Other Stockholders Equity 645,761
Total Stockholder Equity (as reported)398,325
Total Stockholder Equity (calculated)398,325
+/-0
Other
Capital Stock24
Cash and Short Term Investments 90,285
Common Stock Shares Outstanding 248,608
Current Deferred Revenue143
Liabilities and Stockholders Equity 558,380
Net Debt -6,460
Net Invested Capital 471,722
Net Working Capital 324,622
Property Plant and Equipment Gross 103,984
Short Long Term Debt Total 83,825



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-30
> Total Assets 
11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
3
16
9
6
8
17,008
15,884
13,225
15,555
13,817
10,690
8,702
31,980
31,951
27,883
25,287
27,227
33,928
29,800
27,824
23,715
19,685
31,742
27,495
23,685
17,595
84,639
72,813
108,019
91,138
117,752
106,345
88,877
78,120
143,274
137,780
127,091
210,524
191,542
189,976
207,673
235,667
232,814
238,640
276,253
308,032
296,932
300,558
348,461
340,788
343,027
348,997
329,182
350,875
376,399
390,618
488,678
510,569
558,380
558,380510,569488,678390,618376,399350,875329,182348,997343,027340,788348,461300,558296,932308,032276,253238,640232,814235,667207,673189,976191,542210,524127,091137,780143,27478,12088,877106,345117,75291,138108,01972,81384,63917,59523,68527,49531,74219,68523,71527,82429,80033,92827,22725,28727,88331,95131,9808,70210,69013,81715,55513,22515,88417,0088691633,619122,9346,8449,2708,68810,1088,0282,6472,6476,5698,7877,80514,65216,6639,03311,253
   > Total Current Assets 
11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
3
16
9
6
8
15,844
14,619
11,982
13,948
12,306
9,173
7,144
31,052
30,788
26,494
22,572
24,088
30,982
27,127
25,240
21,290
17,358
29,494
25,360
21,657
15,683
44,271
31,444
63,167
46,419
73,630
62,503
44,530
38,334
103,889
97,323
85,820
165,488
142,990
139,549
153,741
177,277
171,355
174,785
208,729
239,800
222,774
224,095
270,402
264,086
266,243
273,699
257,013
276,419
303,691
318,193
331,410
351,814
399,563
399,563351,814331,410318,193303,691276,419257,013273,699266,243264,086270,402224,095222,774239,800208,729174,785171,355177,277153,741139,549142,990165,48885,82097,323103,88938,33444,53062,50373,63046,41963,16731,44444,27115,68321,65725,36029,49417,35821,29025,24027,12730,98224,08822,57226,49430,78831,0527,1449,17312,30613,94811,98214,61915,8448691633,619122,9346,8449,2708,68810,1088,0282,6472,6476,5698,7877,80514,65216,6639,03311,253
       Cash And Cash Equivalents 
11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
3
16
9
6
8
14,240
12,888
10,720
12,536
10,321
7,653
5,380
26,149
26,518
17,869
13,952
17,199
16,564
7,822
9,178
10,441
8,925
12,549
7,906
9,915
8,543
25,574
13,601
43,108
26,120
55,154
42,367
22,755
16,534
73,616
48,006
26,752
101,236
75,781
59,675
55,921
61,966
42,409
34,411
51,089
69,505
52,415
34,906
86,522
69,204
62,513
74,157
51,352
45,325
88,244
86,707
103,147
71,625
90,285
90,28571,625103,14786,70788,24445,32551,35274,15762,51369,20486,52234,90652,41569,50551,08934,41142,40961,96655,92159,67575,781101,23626,75248,00673,61616,53422,75542,36755,15426,12043,10813,60125,5748,5439,9157,90612,5498,92510,4419,1787,82216,56417,19913,95217,86926,51826,1495,3807,65310,32112,53610,72012,88814,2408691633,619122,9346,8449,2708,68810,1088,0282,6472,6476,5698,7877,80514,65216,6639,03311,253
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,935
2,203
6,314
6,320
4,653
11,512
15,930
11,764
6,368
2,695
11,271
11,027
5,390
245
0
0
1,500
1,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000001,5001,500002455,39011,02711,2712,6956,36811,76415,93011,5124,6536,3206,3142,2032,93500000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
220
62
39
326
237
335
0
484
804
562
384
351
522
1,201
924
944
827
1,328
1,018
840
2,292
1,500
3,880
3,658
3,797
4,127
1,392
1,310
5,087
7,315
3,470
7,108
6,514
6,335
13,237
15,362
23,545
20,393
28,577
25,630
18,884
20,902
15,505
26,518
36,732
31,319
27,421
49,621
30,113
50,140
49,999
99,412
109,726
109,72699,41249,99950,14030,11349,62127,42131,31936,73226,51815,50520,90218,88425,63028,57720,39323,54515,36213,2376,3356,5147,1083,4707,3155,0871,3101,3924,1273,7973,6583,8801,5002,2928401,0181,3288279449241,2015223513845628044840335237326396222000000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
428
308
190
216
651
734
223
299
598
395
286
144
613
399
267
111
745
638
482
314
747
3,254
2,924
2,726
2,703
4,863
4,262
3,532
4,099
3,193
3,433
5,067
9,711
9,387
7,573
6,093
11,605
11,404
11,718
4,339
11,039
10,800
10,745
5,095
4,379
5,219
5,107
5,334
3,741
5,524
9,545
8,029
8,589
8,088
8,0888,5898,0299,5455,5243,7415,3345,1075,2194,3795,09510,74510,80011,0394,33911,71811,40411,6056,0937,5739,3879,7115,0673,4333,1934,0993,5324,2624,8632,7032,7262,9243,2547473144826387451112673996131442863955982992237346512161903084280000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,165
1,265
1,243
1,607
1,512
1,518
1,558
927
1,164
1,389
2,716
3,139
2,946
2,673
2,584
2,424
2,327
2,248
2,136
2,028
1,912
40,368
41,369
44,852
44,718
44,122
43,842
44,347
39,786
39,385
40,456
41,270
45,036
48,552
50,428
53,933
58,390
61,459
63,855
67,523
68,232
74,158
76,463
78,059
76,701
76,784
75,298
72,169
74,456
72,708
72,425
157,268
158,755
158,817
158,817158,755157,26872,42572,70874,45672,16975,29876,78476,70178,05976,46374,15868,23267,52363,85561,45958,39053,93350,42848,55245,03641,27040,45639,38539,78644,34743,84244,12244,71844,85241,36940,3681,9122,0282,1362,2482,3272,4242,5842,6732,9463,1392,7161,3891,1649271,5581,5181,5121,6071,2431,2651,1650000000000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
815
825
804
779
802
850
811
765
829
1,039
2,381
2,841
2,738
2,628
2,519
2,397
2,296
2,221
2,109
2,001
1,882
28,627
29,756
30,467
30,616
30,337
30,363
30,116
29,695
29,444
30,713
31,741
35,061
37,373
42,405
45,852
50,373
53,316
55,085
58,198
60,327
65,502
67,282
68,746
67,618
66,309
64,568
63,470
64,714
63,478
53,694
63,341
57,710
66,462
66,46257,71063,34153,69463,47864,71463,47064,56866,30967,61868,74667,28265,50260,32758,19855,08553,31650,37345,85242,40537,37335,06131,74130,71329,44429,69530,11630,36330,33730,61630,46729,75628,6271,8822,0012,1092,2212,2962,3972,5192,6282,7382,8412,3811,0398297658118508027798048258150000000000000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,530
3,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5300000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,011
5,737
4,849
4,638
4,427
4,216
4,004
3,793
3,582
3,371
3,159
2,981
2,802
2,623
2,444
2,265
2,086
1,908
1,729
1,550
1,371
1,192
1,013
835
656
477
499
321
479
485
460
452
527
5274524604854793214994776568351,0131,1921,3711,5501,7291,9082,0862,2652,4442,6232,8022,9813,1593,3713,5823,7934,0044,2164,4274,6384,8495,7376,0110000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
349
440
439
828
709
668
747
163
335
350
334
298
208
45
65
28
31
27
27
27
30
11,742
11,614
14,385
5,935
5,829
5,735
6,697
2,768
2,829
2,843
2,840
3,465
4,847
4,653
6,366
2,223
2,527
3,334
4,067
2,826
3,756
4,459
4,770
0
6,289
0
0
0
0
0
0
0
0
000000006,28904,7704,4593,7562,8264,0673,3342,5272,2236,3664,6534,8473,4652,8402,8432,8292,7686,6975,7355,8295,93514,38511,61411,74230272727312865452082983343503351637476687098284394403490000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
245
203
282
150
308
323
307
272
181
18
38
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000040381818127230732330815028220324500000000000000000000000000
> Total Liabilities 
11,253
9,033
16,663
14,652
7,805
8,787
6,569
2,647
2,647
8,028
10,108
8,688
9,270
6,844
2,934
12
3,619
5
6
10
10
5
1,258
1,228
1,618
6,132
7,417
8,962
9,438
10,407
16,048
15,580
16,042
21,219
20,497
20,280
22,910
22,894
23,054
27,826
27,648
28,142
28,353
56,957
59,821
67,686
68,112
65,993
69,139
69,106
68,081
96,368
101,662
100,898
114,188
114,662
118,600
119,424
123,163
121,220
135,860
135,080
181,099
182,532
200,173
196,487
195,133
196,265
197,559
193,976
197,169
188,130
158,728
139,660
137,150
160,055
160,055137,150139,660158,728188,130197,169193,976197,559196,265195,133196,487200,173182,532181,099135,080135,860121,220123,163119,424118,600114,662114,188100,898101,66296,36868,08169,10669,13965,99368,11267,68659,82156,95728,35328,14227,64827,82623,05422,89422,91020,28020,49721,21916,04215,58016,04810,4079,4388,9627,4176,1321,6181,2281,25851010653,619122,9346,8449,2708,68810,1088,0282,6472,6476,5698,7877,80514,65216,6639,03311,253
   > Total Current Liabilities 
3,616
3,866
3,572
10,072
8,508
8,409
11,058
15,958
15,958
7,458
6,858
11,508
9,908
5,808
6,708
12
8,608
5
6
10
10
5
1,027
1,006
1,404
1,817
2,101
2,029
2,517
3,658
4,303
3,797
4,119
4,198
3,787
3,200
4,298
4,217
4,291
5,083
9,208
11,223
12,958
15,645
13,339
9,440
9,443
6,917
9,893
9,625
8,338
10,129
15,150
14,028
13,908
12,880
16,474
19,947
21,206
18,186
32,337
30,378
31,567
28,072
44,440
39,267
36,728
41,952
41,841
49,806
53,088
44,177
44,891
55,542
53,498
74,941
74,94153,49855,54244,89144,17753,08849,80641,84141,95236,72839,26744,44028,07231,56730,37832,33718,18621,20619,94716,47412,88013,90814,02815,15010,1298,3389,6259,8936,9179,4439,44013,33915,64512,95811,2239,2085,0834,2914,2174,2983,2003,7874,1984,1193,7974,3033,6582,5172,0292,1011,8171,4041,0061,02751010658,608126,7085,8089,90811,5086,8587,45815,95815,95811,0588,4098,50810,0723,5723,8663,616
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
10
12
12
12
12
13
13
13
14
14
14
14
15
15
15
16
4,477
6,128
6,701
6,667
3,860
3,318
40,467
58
59
60
419
446
459
458
388
422
552
731
636
772
1,002
591
1,308
1,159
1,442
905
1,912
1,959
1,966
1,045
2,186
2,284
1,193
1,218
1,188
1,127
1,1271,1881,2181,1932,2842,1861,0451,9661,9591,9129051,4421,1591,3085911,00277263673155242238845845944641960595840,4673,3183,8606,6676,7016,1284,4771615151514141414131313121212121010100000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
0
0
0
15
0
0
0
6,111
17,544
30,855
29,369
40,211
40,467
40,899
0
0
210
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000002100040,89940,46740,21129,36930,85517,5446,1110001500014000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
5
509
791
891
1,059
1,379
1,159
1,483
2,709
2,764
2,340
2,445
1,779
1,779
1,648
2,185
2,088
2,468
3,317
2,777
2,565
3,904
4,672
9,156
5,921
5,718
3,101
5,268
5,900
5,480
6,788
8,960
9,175
9,152
6,910
7,980
11,074
12,153
6,167
17,283
12,429
14,115
11,388
25,198
13,229
12,956
12,085
10,851
15,660
17,186
14,179
16,020
20,219
20,607
29,769
29,76920,60720,21916,02014,17917,18615,66010,85112,08512,95613,22925,19811,38814,11512,42917,2836,16712,15311,0747,9806,9109,1529,1758,9606,7885,4805,9005,2683,1015,7185,9219,1564,6723,9042,5652,7773,3172,4682,0882,1851,6481,7791,7792,4452,3402,7642,7091,4831,1591,3791,05989179150951000000000000000000000
       Other Current Liabilities 
3,616
3,866
3,572
10,072
8,508
8,409
11,058
15,958
0
7,458
6,858
11,508
9,908
5,808
6,708
12
9
5
6
10
10
5
508
205
503
747
710
789
947
936
1,451
1,368
1,585
2,405
1,918
1,463
1,949
1,968
1,662
1,605
1,792
2,385
2,191
4,161
4,037
3,376
3,582
3,586
4,394
3,492
2,087
2,528
4,304
4,252
4,031
5,195
7,523
7,999
8,274
11,104
13,909
17,215
16,001
15,381
17,658
24,990
21,716
27,766
28,881
32,919
32,598
23,750
27,535
30,481
10,953
41,202
41,20210,95330,48127,53523,75032,59832,91928,88127,76621,71624,99017,65815,38116,00117,21513,90911,1048,2747,9997,5235,1954,0314,2524,3042,5282,0873,4924,3943,5863,5823,3764,0374,1612,1912,3851,7921,6051,6621,9681,9491,4631,9182,4051,5851,3681,45193694778971074750320550851010659126,7085,8089,90811,5086,8587,458015,95811,0588,4098,50810,0723,5723,8663,616
   > Long-term Liabilities 
3,616
3,866
3,572
10,072
8,508
8,409
11,058
15,958
15,958
7,458
6,858
11,508
9,908
5,808
6,708
0
8,608
0
0
0
0
0
231
222
214
4,314
5,316
6,933
6,921
6,749
11,744
11,784
11,924
17,021
16,710
17,080
18,612
18,677
18,763
22,743
18,440
16,919
15,395
41,312
46,482
58,246
58,669
59,076
59,246
59,481
59,743
86,240
86,512
86,870
100,280
101,782
102,127
99,477
101,957
103,034
103,523
104,702
149,533
154,460
155,733
157,220
158,405
154,312
155,718
144,170
144,081
143,953
113,837
84,118
83,652
85,114
85,11483,65284,118113,837143,953144,081144,170155,718154,312158,405157,220155,733154,460149,533104,702103,523103,034101,95799,477102,127101,782100,28086,87086,51286,24059,74359,48159,24659,07658,66958,24646,48241,31215,39516,91918,44022,74318,76318,67718,61217,08016,71017,02111,92411,78411,7446,7496,9216,9335,3164,314214222231000008,60806,7085,8089,90811,5086,8587,45815,95815,95811,0588,4098,50810,0723,5723,8663,616
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
87
84
81
3,851
4,869
4,888
4,909
4,930
9,736
9,765
9,915
14,824
14,940
14,037
14,156
14,283
14,413
18,078
13,818
12,341
10,861
11,151
16,324
28,128
28,377
28,772
29,040
29,320
42,347
83,774
84,095
69,594
97,961
99,511
99,904
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000099,90499,51197,96169,59484,09583,77442,34729,32029,04028,77228,37728,12816,32411,15110,86112,34113,81818,07814,41314,28314,15614,03714,94014,8249,9159,7659,7364,9304,9094,8884,8693,8518184870000000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
245
203
282
150
308
323
307
272
181
18
38
0
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000040381818127230732330815028220324500000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
144
138
133
356
313
1,911
1,878
1,686
1,875
1,886
1,876
2,064
1,637
1,610
3,024
2,962
2,918
2,875
2,832
2,787
2,744
2,712
2,701
15,275
18,203
18,206
18,100
18,047
2,514
2,465
2,417
2,368
2,319
2,271
2,222
2,173,584
2,125
2,083
2,244
2,373
3,826
3,778
3,731
3,683
0
3,778
0
0
0
0
0
0
0
0
000000003,77803,6833,7313,7783,8262,3732,2442,0832,1252,173,5842,2222,2712,3192,3682,4172,4652,51418,04718,10018,20618,20315,2752,7012,7122,7442,7872,8322,8752,9182,9623,0241,6101,6372,0641,8761,8861,8751,6861,8781,9113133561331381440000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
144
139
133
128
315
1,913
1,879
1,686
1,876
1,886
1,876
2,065
1,638
1,611
3,023
2,962
2,918
2,875
2,831
2,788
2,745
2,619
2,583
2,547
2,511
2,476
2,440
2,404
2,369
2,333
2,297
2,262
2,226
2,190
2,154
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000002,1542,1902,2262,2622,2972,3332,3692,4042,4402,4762,5112,5472,5832,6192,7452,7882,8312,8752,9182,9623,0231,6111,6382,0651,8761,8861,8761,6861,8791,9133151281331391440000000000000000000000
> Total Stockholder Equity
7,637
5,167
13,091
4,580
-703
378
-4,489
-13,311
0
570
3,250
-2,820
-638
1,036
-3,774
0
-4,989
-2
10
-1
-4
3
15,750
14,656
11,607
9,424
6,401
1,728
-736
21,573
15,904
12,303
9,245
6,009
13,430
9,520
4,914
821
-3,369
3,916
-152
-4,457
-10,758
27,682
12,993
40,333
23,025
51,759
37,206
19,770
10,039
46,906
36,118
26,193
96,336
76,879
71,376
88,249
112,504
111,594
102,780
141,173
126,933
114,401
100,385
151,974
145,655
146,762
151,437
135,206
153,706
188,269
231,890
349,018
373,419
398,325
398,325373,419349,018231,890188,269153,706135,206151,437146,762145,655151,974100,385114,401126,933141,173102,780111,594112,50488,24971,37676,87996,33626,19336,11846,90610,03919,77037,20651,75923,02540,33312,99327,682-10,758-4,457-1523,916-3,3698214,9149,52013,4306,0099,24512,30315,90421,573-7361,7286,4019,42411,60714,65615,7503-4-110-2-4,9890-3,7741,036-638-2,8203,2505700-13,311-4,489378-7034,58013,0915,1677,637
   Common Stock
0
0
0
0
0
0
0
250
0
250
250
250
250
250
250
0
250
0
0
0
0
0
5
5
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
3
3
5
5
5
5
5
5
6
6
6
9
9
9
10
12
13
14
20
20
20
20
22
22
22
23
23
23
23
24
24
24
24
242424242323232322222220202020141312109996665555553311111111111111111005500000250025025025025025025002500000000
   Retained Earnings -247,460-281,679-308,583-420,479-456,388-488,450-506,256-488,611-491,176-484,805-478,017-465,785-450,885-437,121-412,113-395,463-377,750-358,845-340,465-321,057-304,140-283,962-264,717-254,156-242,717-229,505-216,437-198,399-183,264-168,516-150,694-137,711-122,508-113,472-106,935-102,376-98,044-92,032-87,420-82,837-77,735-73,055-69,450-65,886-62,502-58,540-52,637-47,935-45,246-40,351-37,109-34,858-31,612-30,405-154-145-140-128-123-118-1140000000000000-38-33
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
141
156
46,151
46,263
46,464
46,533
46,751
46,974
47,199
74,209
74,443
74,803
75,130
75,457
86,485
87,253
87,750
88,240
88,662
101,959
102,222
102,476
102,712
150,188
150,701
191,022
191,537
235,018
235,601
236,203
239,540
289,617
290,268
290,904
380,289
381,011
392,424
428,704
471,337
489,331
498,230
553,266
564,034
565,266
566,150
629,969
630,438
637,916
0
0
0
0
0
0
0
0
00000000637,916630,438629,969566,150565,266564,034553,266498,230489,331471,337428,704392,424381,011380,289290,904290,268289,617239,540236,203235,601235,018191,537191,022150,701150,188102,712102,476102,222101,95988,66288,24087,75087,25386,48575,45775,13074,80374,44374,20947,19946,97446,75146,53346,46446,26346,15115614100000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
7,670
5,205
13,091
4,580
-703
378
-4,489
-13,561
0
320
3,000
-3,070
-888
786
-4,024
113
-5,121
122
139
139
141
156
46,151
46,263
46,464
46,532
46,751
46,974
47,199
74,209
74,443
74,803
75,130
75,457
86,485
87,253
87,750
88,240
88,662
101,959
102,222
102,476
102,712
150,188
150,701
191,022
193,340
235,018
235,601
236,203
239,540
289,617
290,268
290,904
380,289
381,011
392,424
428,704
471,337
489,331
498,230
553,266
564,034
565,266
566,150
629,969
630,438
637,916
640,026
641,439
642,133
644,634
652,345
657,601
655,074
645,761
645,761655,074657,601652,345644,634642,133641,439640,026637,916630,438629,969566,150565,266564,034553,266498,230489,331471,337428,704392,424381,011380,289290,904290,268289,617239,540236,203235,601235,018193,340191,022150,701150,188102,712102,476102,222101,95988,66288,24087,75087,25386,48575,45775,13074,80374,44374,20947,19946,97446,75146,53246,46446,26346,151156141139139122-5,121113-4,024786-888-3,0703,0003200-13,561-4,489378-7034,58013,0915,2057,670



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue426,454
Cost of Revenue-206,901
Gross Profit219,553219,553
 
Operating Income (+$)
Gross Profit219,553
Operating Expense-80,570
Operating Income138,983138,983
 
Operating Expense (+$)
Research Development1,813
Selling General Administrative74,124
Selling And Marketing Expenses0
Operating Expense80,57075,937
 
Net Interest Income (+$)
Interest Income2,097
Interest Expense-13,930
Other Finance Cost-0
Net Interest Income-11,833
 
Pretax Income (+$)
Operating Income138,983
Net Interest Income-11,833
Other Non-Operating Income Expenses0
Income Before Tax (EBT)125,714152,252
EBIT - interestExpense = 125,714
125,714
211,603
Interest Expense13,930
Earnings Before Interest and Taxes (EBIT)139,644139,644
Earnings Before Interest and Taxes (EBITDA)147,689
 
After tax Income (+$)
Income Before Tax125,714
Tax Provision--71,959
Net Income From Continuing Ops197,673197,673
Net Income197,673
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses282,838
Total Other Income/Expenses Net-13,26911,833
 

Technical Analysis of ADMA Biologics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of ADMA Biologics Inc. The general trend of ADMA Biologics Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine ADMA Biologics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. ADMA Biologics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ADMA Biologics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 15.14 < 15.60 < 16.62.

The bearish price targets are: 14.03 > 13.82 > 13.50.

Know someone who trades $ADMA? Share this with them.👇

ADMA Biologics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ADMA Biologics Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ADMA Biologics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ADMA Biologics Inc. The current macd is -0.30370672.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the ADMA Biologics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for ADMA Biologics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the ADMA Biologics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
ADMA Biologics Inc Daily Moving Average Convergence/Divergence (MACD) ChartADMA Biologics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ADMA Biologics Inc. The current adx is 16.22.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy ADMA Biologics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
ADMA Biologics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ADMA Biologics Inc. The current sar is 14.17.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
ADMA Biologics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ADMA Biologics Inc. The current rsi is 50.60. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
ADMA Biologics Inc Daily Relative Strength Index (RSI) ChartADMA Biologics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ADMA Biologics Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the ADMA Biologics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
ADMA Biologics Inc Daily Stochastic Oscillator ChartADMA Biologics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ADMA Biologics Inc. The current cci is 81.60.

ADMA Biologics Inc Daily Commodity Channel Index (CCI) ChartADMA Biologics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ADMA Biologics Inc. The current cmo is 13.03.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
ADMA Biologics Inc Daily Chande Momentum Oscillator (CMO) ChartADMA Biologics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ADMA Biologics Inc. The current willr is -24.71910112.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that ADMA Biologics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
ADMA Biologics Inc Daily Williams %R ChartADMA Biologics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of ADMA Biologics Inc.

ADMA Biologics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ADMA Biologics Inc. The current atr is 0.58477752.

ADMA Biologics Inc Daily Average True Range (ATR) ChartADMA Biologics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ADMA Biologics Inc. The current obv is 198,151,437.

ADMA Biologics Inc Daily On-Balance Volume (OBV) ChartADMA Biologics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ADMA Biologics Inc. The current mfi is 54.32.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
ADMA Biologics Inc Daily Money Flow Index (MFI) ChartADMA Biologics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ADMA Biologics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-06-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-08-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-09-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-15STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-10-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-10-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-10-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

ADMA Biologics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ADMA Biologics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.596
Ma 20Greater thanMa 5014.728
Ma 50Greater thanMa 10015.879
Ma 100Greater thanMa 20017.224
OpenGreater thanClose14.710
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of ADMA Biologics Inc with someone you think should read this too:
  • Are you bullish or bearish on ADMA Biologics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about ADMA Biologics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ADMA Biologics Inc

I send you an email if I find something interesting about ADMA Biologics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about ADMA Biologics Inc.

Receive notifications about ADMA Biologics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.